Chronic Pain - Pipeline Review, H2 2016

Chronic Pain - Pipeline Review, H2 2016


  • Products Id :- GMDHC8545IDB
  • |
  • Pages: 335
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chronic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Chronic Pain - Pipeline Review, H2 2016', provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Pain

- The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects

- The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chronic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Pain

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Chronic Pain Overview 12

Therapeutics Development 13

Pipeline Products for Chronic Pain - Overview 13

Pipeline Products for Chronic Pain - Comparative Analysis 14

Chronic Pain - Therapeutics under Development by Companies 15

Chronic Pain - Therapeutics under Investigation by Universities/Institutes 22

Chronic Pain - Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Chronic Pain - Products under Development by Companies 27

Chronic Pain - Products under Investigation by Universities/Institutes 35

Chronic Pain - Companies Involved in Therapeutics Development 36

AbbVie Inc 36

Acadia Pharmaceuticals Inc. 37

Adynxx, Inc. 38

Allergan Plc 39

Amorsa Therapeutics Inc. 40

arGEN-X BV 41

Asana BioSciences, LLC 42

AskAt Inc. 43

Astraea Therapeutics, LLC 44

Axsome Therapeutics, Inc. 45

BioDelivery Sciences International, Inc. 46

Biogen Inc 47

Bionomics Limited 48

Camurus AB 49

Cara Therapeutics, Inc. 50

Centrexion Therapeutics Corp 51

ChironWells GmbH 52

Collegium Pharmaceutical, Inc. 53

Crinetics Pharmaceuticals, Inc. 54

Cyclenium Pharma, Inc. 55

Cytogel Pharma, LLC 56

Daewoong Pharmaceutical Co., Ltd. 57

Daiichi Sankyo Company, Limited 58

Dompe Farmaceutici S.p.A. 59

Echo Pharmaceuticals B.V. 60

Egalet Corporation 61

Eli Lilly and Company 62

Elite Pharmaceuticals, Inc. 63

Glenmark Pharmaceuticals Ltd. 64

Grunenthal GmbH 65

Heron Therapeutics, Inc. 66

INSYS Therapeutics, Inc. 67

Johnson & Johnson 68

Kareus Therapeutics, SA 69

KPI Therapeutics, Inc. 70

Kymab Limited 71

Laboratorios Del Dr. Esteve S.A. 72

Lohocla Research Corporation 73

Lpath, Inc. 74

MD Biosciences GmbH 75

Merck & Co., Inc. 76

Moberg Pharma AB 77

Mundipharma International Ltd 78

Nanomerics Ltd 79

Nektar Therapeutics 80

Neura Therapeutik, LLC 81

Orion Oyj 82

Pacira Pharmaceuticals, Inc. 83

Pain Therapeutics, Inc. 84

PeriphaGen, Inc. 85

Pfizer Inc. 86

Phosphagenics Limited 87

Prismic Pharmaceuticals, Inc. 88

Purdue Pharma LP 89

Relmada Therapeutics, Inc. 90

Ribomic Inc. 91

Sea4Us 92

Shulov Innovative Science Ltd. 93

Synactix Pharmaceuticals, Inc. 94

Syntrix Biosystems, Inc. 95

Teva Pharmaceutical Industries Ltd. 96

Therapix Biosciences Ltd. 97

Trevena, Inc. 98

Voyager Therapeutics, Inc. 99

Yooyoung Pharmaceutical Co., Ltd. 100

Zynerba Pharmaceuticals, Inc. 101

Chronic Pain - Therapeutics Assessment 102

Assessment by Monotherapy Products 102

Assessment by Combination Products 103

Assessment by Target 104

Assessment by Mechanism of Action 111

Assessment by Route of Administration 118

Assessment by Molecule Type 120

Drug Profiles 122

(celecoxib + tramadol hydrochloride) - Drug Profile 122

(hydrocodone bitartrate + palmidrol) - Drug Profile 124

(morphine sulfate + palmidrol) - Drug Profile 125

(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 126

(oxycodone hydrochloride + palmidrol) - Drug Profile 127

(palmidrol + pregabalin) - Drug Profile 128

A-200 - Drug Profile 129

AGN-XX - Drug Profile 130

AGN-YY - Drug Profile 131

AMS-520 - Drug Profile 132

ASN-008 - Drug Profile 133

AVLX-144 - Drug Profile 134

AXS-06 - Drug Profile 135

AYX-1 - Drug Profile 136

AYX-2 - Drug Profile 138

BBI-11008 - Drug Profile 139

bupivacaine - Drug Profile 140

bupivacaine hydrochloride - Drug Profile 142

buprenorphine hydrochloride - Drug Profile 144

buprenorphine hydrochloride depot - Drug Profile 146

buprenorphine hydrochloride ER - Drug Profile 147

buprenorphine hydrochloride long acting - Drug Profile 149

cebranopadol - Drug Profile 150

cetirizine hydrochloride + cromolyn sodium - Drug Profile 153

cetuximab - Drug Profile 154

CNTX-0290 - Drug Profile 160

CNV-3000164 - Drug Profile 161

CNV-3000223 - Drug Profile 162

CR-4056 - Drug Profile 163

CR-701 - Drug Profile 164

CRB-0089 - Drug Profile 165

Cyt-1010 - Drug Profile 166

dexmedetomidine hydrochloride - Drug Profile 168

DF-2593A - Drug Profile 170

difelikefalin - Drug Profile 171

dronabinol - Drug Profile 178

DS-1971 - Drug Profile 180

DWJ-208 - Drug Profile 181

ECP-1014 - Drug Profile 182

Egalet-003 - Drug Profile 183

fluticasone propionate - Drug Profile 184

FY-101C - Drug Profile 185

FY-103B - Drug Profile 186

GBR-900 - Drug Profile 187

Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile 188

grapiprant - Drug Profile 189

HPI-201 - Drug Profile 191

HS-731 - Drug Profile 192

hydrocodone bitartrate ER - Drug Profile 193

hydrocodone bitartrate ER - Drug Profile 196

hydrocodone bitartrate ER - Drug Profile 197

hydromorphone hydrochloride - Drug Profile 198

Kindolor - Drug Profile 199

KY-1017 - Drug Profile 200

L-779976 - Drug Profile 201

lacosamide - Drug Profile 202

LEVI-04 - Drug Profile 203

levorphanol tartrate ER - Drug Profile 204

Lpathomab - Drug Profile 206

MD-354 - Drug Profile 209

Monoclonal Antibodies for Chronic Pain - Drug Profile 210

Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile 211

morphine sulfate ER - Drug Profile 212

MR-309 - Drug Profile 216

NET-END - Drug Profile 218

NKTR-181 - Drug Profile 219

NL-001 - Drug Profile 222

NL-002 - Drug Profile 223

NM-0127 - Drug Profile 224

Omnitram - Drug Profile 225

onabotulinumtoxin A - Drug Profile 226

OSX-300 - Drug Profile 231

OSX-300 Backups - Drug Profile 232

oxycodone hydrochloride ER - Drug Profile 233

oxycodone hydrochloride ER - Drug Profile 236

oxycodone hydrochloride ER - Drug Profile 237

oxymorphone hydrochloride - Drug Profile 239

oxymorphone hydrochloride ER - Drug Profile 240

PAC-CP - Drug Profile 241

palmidrol - Drug Profile 242

Peptide to Block Cav2.2 for CNS Disorders - Drug Profile 243

Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile 244

Peptides to Target TRPV1 for Pain and Itch - Drug Profile 245

PN-6047 - Drug Profile 246

PRC-062 - Drug Profile 247

Prostatic Acid Phosphatase - Drug Profile 248

PspTx-3 - Drug Profile 249

raxatrigine hydrochloride - Drug Profile 250

RBM-005 - Drug Profile 253

REL-1017 - Drug Profile 254

SAFit2 - Drug Profile 257

Small Molecule for Chronic Pain - Drug Profile 258

Small Molecule for Chronic Pain - Drug Profile 259

Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile 260

Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile 261

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile 262

Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 264

Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile 265

Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile 266

Small Molecules for Chronic Wound Pain - Drug Profile 267

Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile 268

Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile 269

Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 270

Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile 271

Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 272

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile 273

Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile 274

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 275

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 276

Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile 277

Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile 278

Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 279

Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 280

Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile 281

Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile 282

Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile 283

Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile 284

Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile 285

SYN-003 - Drug Profile 286

Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 287

tanezumab - Drug Profile 288

tapentadol hydrochloride IR - Drug Profile 291

TRV-734 - Drug Profile 293

U-2902 - Drug Profile 295

UMB-425 - Drug Profile 297

Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile 298

VM-902A - Drug Profile 299

VYNAV-01 - Drug Profile 300

XT-101 - Drug Profile 301

YYC-301 - Drug Profile 302

ZEP-3 - Drug Profile 303

ZYN-001 - Drug Profile 304

Chronic Pain - Dormant Projects 305

Chronic Pain - Discontinued Products 314

Chronic Pain - Product Development Milestones 317

Featured News & Press Releases 317

Appendix 325

Methodology 325

Coverage 325

Secondary Research 325

Primary Research 325

Expert Panel Validation 325

Contact Us 325

Disclaimer 326

List of Figures

Number of Products under Development for Chronic Pain, H2 2016 22

Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 24

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Products, H2 2016 34

Assessment by Monotherapy Products, H2 2016 111

Assessment by Combination Products, H2 2016 112

Number of Products by Top 10 Targets, H2 2016 113

Number of Products by Stage and Top 10 Targets, H2 2016 113

Number of Products by Top 10 Mechanism of Actions, H2 2016 120

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 120

Number of Products by Top 10 Routes of Administration, H2 2016 127

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 127

Number of Products by Top 10 Molecule Types, H2 2016 129

Number of Products by Stage and Top 10 Molecule Types, H2 2016 129

List of Tables

Number of Products under Development for Chronic Pain, H2 2016 22

Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016 23

Number of Products under Development by Companies, H2 2016 25

Number of Products under Development by Companies, H2 2016 (Contd..1) 26

Number of Products under Development by Companies, H2 2016 (Contd..2) 27

Number of Products under Development by Companies, H2 2016 (Contd..3) 28

Number of Products under Development by Companies, H2 2016 (Contd..4) 29

Number of Products under Development by Companies, H2 2016 (Contd..5) 30

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Development, H2 2016 34

Comparative Analysis by Unknown Stage Development, H2 2016 35

Products under Development by Companies, H2 2016 36

Products under Development by Companies, H2 2016 (Contd..1) 37

Products under Development by Companies, H2 2016 (Contd..2) 38

Products under Development by Companies, H2 2016 (Contd..3) 39

Products under Development by Companies, H2 2016 (Contd..4) 40

Products under Development by Companies, H2 2016 (Contd..5) 41

Products under Development by Companies, H2 2016 (Contd..6) 42

Products under Development by Companies, H2 2016 (Contd..7) 43

Products under Investigation by Universities/Institutes, H2 2016 44

Chronic Pain - Pipeline by AbbVie Inc, H2 2016 45

Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016 46

Chronic Pain - Pipeline by Adynxx, Inc., H2 2016 47

Chronic Pain - Pipeline by Allergan Plc, H2 2016 48

Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016 49

Chronic Pain - Pipeline by arGEN-X BV, H2 2016 50

Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016 51

Chronic Pain - Pipeline by AskAt Inc., H2 2016 52

Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016 53

Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016 54

Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016 55

Chronic Pain - Pipeline by Biogen Inc, H2 2016 56

Chronic Pain - Pipeline by Bionomics Limited, H2 2016 57

Chronic Pain - Pipeline by Camurus AB, H2 2016 58

Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 59

Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 60

Chronic Pain - Pipeline by ChironWells GmbH, H2 2016 61

Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016 62

Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 63

Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016 64

Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016 65

Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 66

Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 67

Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 68

Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016 69

Chronic Pain - Pipeline by Egalet Corporation, H2 2016 70

Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016 71

Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016 72

Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 73

Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016 74

Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016 75

Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016 76

Chronic Pain - Pipeline by Johnson & Johnson, H2 2016 77

Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016 78

Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 79

Chronic Pain - Pipeline by Kymab Limited, H2 2016 80

Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 81

Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016 82

Chronic Pain - Pipeline by Lpath, Inc., H2 2016 83

Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016 84

Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016 85

Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016 86

Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016 87

Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016 88

Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016 89

Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016 90

Chronic Pain - Pipeline by Orion Oyj, H2 2016 91

Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 92

Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016 93

Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016 94

Chronic Pain - Pipeline by Pfizer Inc., H2 2016 95

Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016 96

Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016 97

Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016 98

Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016 99

Chronic Pain - Pipeline by Ribomic Inc., H2 2016 100

Chronic Pain - Pipeline by Sea4Us, H2 2016 101

Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016 102

Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016 103

Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016 104

Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 105

Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016 106

Chronic Pain - Pipeline by Trevena, Inc., H2 2016 107

Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016 108

Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 109

Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 110

Assessment by Monotherapy Products, H2 2016 111

Assessment by Combination Products, H2 2016 112

Number of Products by Stage and Target, H2 2016 114

Number of Products by Stage and Mechanism of Action, H2 2016 121

Number of Products by Stage and Route of Administration, H2 2016 128

Number of Products by Stage and Molecule Type, H2 2016 130

Chronic Pain - Dormant Projects, H2 2016 314

Chronic Pain - Dormant Projects (Contd..1), H2 2016 315

Chronic Pain - Dormant Projects (Contd..2), H2 2016 316

Chronic Pain - Dormant Projects (Contd..3), H2 2016 317

Chronic Pain - Dormant Projects (Contd..4), H2 2016 318

Chronic Pain - Dormant Projects (Contd..5), H2 2016 319

Chronic Pain - Dormant Projects (Contd..6), H2 2016 320

Chronic Pain - Dormant Projects (Contd..7), H2 2016 321

Chronic Pain - Dormant Projects (Contd..8), H2 2016 322

Chronic Pain - Discontinued Products, H2 2016 323

Chronic Pain - Discontinued Products (Contd..1), H2 2016 324

Chronic Pain - Discontinued Products (Contd..2), H2 2016 325

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc

Acadia Pharmaceuticals Inc.

Adynxx, Inc.

Allergan Plc

Amorsa Therapeutics Inc.

arGEN-X BV

Asana BioSciences, LLC

AskAt Inc.

Astraea Therapeutics, LLC

Axsome Therapeutics, Inc.

BioDelivery Sciences International, Inc.

Biogen Inc

Bionomics Limited

Camurus AB

Cara Therapeutics, Inc.

Centrexion Therapeutics Corp

ChironWells GmbH

Collegium Pharmaceutical, Inc.

Crinetics Pharmaceuticals, Inc.

Cyclenium Pharma, Inc.

Cytogel Pharma, LLC

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Dompe Farmaceutici S.p.A.

Echo Pharmaceuticals B.V.

Egalet Corporation

Eli Lilly and Company

Elite Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Ltd.

Grunenthal GmbH

Heron Therapeutics, Inc.

INSYS Therapeutics, Inc.

Johnson & Johnson

Kareus Therapeutics, SA

KPI Therapeutics, Inc.

Kymab Limited

Laboratorios Del Dr. Esteve S.A.

Lohocla Research Corporation

Lpath, Inc.

MD Biosciences GmbH

Merck & Co., Inc.

Moberg Pharma AB

Mundipharma International Ltd

Nanomerics Ltd

Nektar Therapeutics

Neura Therapeutik, LLC

Orion Oyj

Pacira Pharmaceuticals, Inc.

Pain Therapeutics, Inc.

PeriphaGen, Inc.

Pfizer Inc.

Phosphagenics Limited

Prismic Pharmaceuticals, Inc.

Purdue Pharma LP

Relmada Therapeutics, Inc.

Ribomic Inc.

Sea4Us

Shulov Innovative Science Ltd.

Synactix Pharmaceuticals, Inc.

Syntrix Biosystems, Inc.

Teva Pharmaceutical Industries Ltd.

Therapix Biosciences Ltd.

Trevena, Inc.

Voyager Therapeutics, Inc.

Yooyoung Pharmaceutical Co., Ltd.

Zynerba Pharmaceuticals, Inc.

Chronic Pain Therapeutic Products under Development, Key Players in Chronic Pain Therapeutics, Chronic Pain Pipeline Overview, Chronic Pain Pipeline, Chronic Pain Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com